戻る
Outlook Therapeutics Inc (OTLK)価格
OTLK 株価推移チャート
OTLK 収入
Outlook Therapeutics Inc
$0.37
6.59%
$0.02
本日現在の状況：Mar 17, 13:01:02 GMT-4
最新の利益結果: Q1 '26
報告済み: 2026-02-17
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
OTLKの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Outlook Therapeutics Inc OTLKの前四半期の収益はどうでしたか？
Outlook Therapeutics Incの収益見積もりはいくらですか？
Outlook Therapeutics Incの収益品質スコアはどれくらいですか？
Outlook Therapeutics Incはいつ収益を報告しますか？
Outlook Therapeutics Incの予想収益はいくらですか？
Outlook Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$0.3519
始値
$0.379
当日レンジ
$0.3602 - $0.4
52週レンジ
$0.3418 - $3.39
取引高
1.4M
平均取引高
5.5M
1株当たり利益(TTM)
-2.71
配当利回り
--
時価総額
$31.1M
OTLKとは何ですか？
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.